Journal Information
Vol. 46. Issue S8.
EPOC: ¿cómo mejorar la atención al paciente?
Pages 20-24 (November 2010)
Share
Share
Download PDF
More article options
Vol. 46. Issue S8.
EPOC: ¿cómo mejorar la atención al paciente?
Pages 20-24 (November 2010)
Full text access
Importancia y variabilidad de los síntomas en la EPOC. Su importancia para el tratamiento
Importance and variability of symptoms in chronic obstructive pulmonary disease. Their significance for treatment
Visits
...
José Luis López-Campos
Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocío, Sevilla, España
Article information
Abstract
Bibliography
Download PDF
Statistics
Resumen

La evaluación de los pacientes con enfermedad pulmonar obstructiva crónica ha dado un cambio en las últimas décadas con la incorporación de valoraciones subjetivas de los pacientes a las mediciones tradicionales basadas en función pulmonar. Una de las variables estudiadas más recientemente es la variabilidad de los síntomas durante el día y, específicamente, la percepción de estos síntomas durante las primeras horas del día. Para valorar este aspecto, recientemente se han desarrollado 2 nuevos cuestionarios de síntomas: el Capacity of Daily Living during the Morning Questionnaire y el Global Chest Symptoms Questionnaire. Hay estudios recientes que empiezan a aportar datos sobre el efecto de los tratamientos disponibles sobre estos síntomas matutinos. Los resultados de estos estudios muestran datos sobre la rapidez de acción de budesónida/ formoterol con un efecto en las actividades matutinas significativo y cercano a la relevancia clínica. De confirmarse estos resultados, esto podría conducir en un futuro hacia estrategias encaminadas a la mejoría sintomática más temprana que conllevara una adherencia mayor al tratamiento.

Palabras clave:
Enfermedad pulmonar obstructiva crónica
Actividades matutinas
Variabilidad clínica
Budesónida/formoterol
Cuestionarios
Abstract

Assessment of patients with COPD has changed in the last few years by adding subjective patient evaluations to traditional measurements based on pulmonary function. One of the most recently studied variables is symptom variability during the day and, specifically, patients’ perceptions of these symptoms in the first few hours of the day. To evaluate this feature, two new symptom questionnaires, the Capacity of Daily Living in the Morning (CDLM) questionnaire and the Global Chest Symptoms Questionnaire (GCSQ), have recently been developed. Recent studies have begun to provide data on the effect of the available treatments on these morning symptoms, yielding information on the rapidity of action of budesonide/formoterol with a significant and nearly clinically relevant effect on morning activities. Confirmation of these results could lead to future strategies designed to earlier symptomatic improvement, which could lead to greater treatment adherence.

Keywords:
Chronic obstructive pulmonary disease
Morning activities
Clinical variability
Budesonide/formoterol
Questionnaires
Full text is only aviable in PDF
Bibliografía
[1.]
R. Rodriguez-Roisin.
Toward a consensus definition for COPD exacerbations.
Chest, 117 (2000), pp. 398S-401S
[2.]
M. Miravitlles.
Tratamiento individualizado de la EPOC: una propuesta de cambio.
Arch Bronconeumol, 45 (2009), pp. 27-34
[3.]
D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, S. Menjoge, et al.
UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
N Engl J Med, 359 (2008), pp. 1543-1554
[4.]
N.M. Clark, J.A. Dodge, M.R. Partridge, F.J. Martinez.
Focusing on outcomes: making the most of COPD interventions.
Int J Chron Obstruct Pulmon Dis, 4 (2009), pp. 61-77
[5.]
J.R. Curtis, DL. Patrick.
The assessment of health status among patients with COPD.
Eur Respir J, 21 (2003), pp. 36s-45s
[6.]
C.M. Fletcher.
The clinical diagnosis of pulmonary emphysema; an experimental study.
Proc R Soc Med, 45 (1952), pp. 577-584
[7.]
R.A. Kinsman, E. Fernandez, M. Schocket, J.F. Dirks, N.A. Covino.
Multidimensional analysis of the symptoms of chronic bronchitis and emphysema.
J Behav Med, 6 (1983), pp. 339-357
[8.]
T. Van der Molen, B.W. Willemse, S. Schokker, N.H. Ten Hacken, D.S. Postma, E.F. Juniper.
Development, validity and responsiveness of the Clinical COPD Questionnaire.
Health Qual Life Outcomes, 1 (2003), pp. 13
[9.]
P.W. Jones, G. Harding, P. Berry, I. Wiklund, W.H. Chen, N. Kline Leidy.
Development and first validation of the COPD Assessment Test.
Eur Respir J, 34 (2009), pp. 648-654
[10.]
M. Miravitlles, J.B. Soriano, F. García-Río, L. Muñoz, E. Duran-Tauleria, G. Sanchez, et al.
Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities.
Thorax, 64 (2009), pp. 863-868
[11.]
M. Montes de Oca, C. Tálamo, R.J. Halbert, R. Perez-Padilla, M.V. Lopez, A. Muiño, et al.
Health status perception and airflow obstruction in five Latin American cities: the PLATINO study.
Respir Med, 103 (2009), pp. 1376-1382
[12.]
J.M. Rodríguez-González Moro, J.L. Izquierdo, E. Antón, P. De Lucas, A. Martín.
MUVICE Study Group. Health-related quality of life in outpatient women with COPD in daily practice: the MUVICE Spanish study.
Respir Med, 103 (2009), pp. 1303-1312
[13.]
J.Z. Reardon, S.C. Lareau, R. ZuWallack.
Functional status and quality of life in chronic obstructive pulmonary disease.
[14.]
J.A. Van Noord, J.L. Aumann, E. Janssens, J. Verhaert, J.J. Smeets, A. Mueller, et al.
Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.
Chest, 129 (2006), pp. 509-517
[15.]
P.L. Brand, D.S. Postma, H.A. Kerstjens, G.H. Koëter.
Relationship of airway hyperresponsiveness to respiratory symptoms and diurnal peak flow variation in patients with obstructive lung disease. The Dutch CNSLD Study Group.
Am Rev Respir Dis, 143 (1991), pp. 916-921
[16.]
C. McCarley, S.K. Hanneman, N. Padhye, M.H. Smolensky.
A pilot home study of temporal variations of symptoms in chronic obstructive lung disease.
Biol Res Nurs, 9 (2007), pp. 8-20
[17.]
M. Miravitlles, A. Anzueto, D. Legnani, L. Forstmeier, M. Fargel.
Patient's perception of exacerbations of COPD–the PERCEIVE study.
Respir Med, 101 (2007), pp. 453-460
[18.]
M.R. Partridge, N. Karlsson, I.R. Small.
Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey.
Curr Med Res Opin, 25 (2009), pp. 2043-2048
[19.]
Partridge MR, Miravitlles M, Ståhl E, Karlsson N, Svensson K, Welte T. Development and validation of the Capacity of Daily Living during the Morning and Global Chest Symptoms Questionnaires in COPD. Eur Respir J. 2010. (En prensa)
[20.]
P. Santus, F. Giovannelli, F. Di Marco, S. Centanni.
Budesonide/formoterol dry powder in asthma: an option for control as maintenance and reliever therapy.
Expert Opin Pharmacother, 11 (2010), pp. 257-267
[21.]
G. Celik, O. Kayacan, S. Beder, G. Durmaz.
Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action.
Respiration, 66 (1999), pp. 434-439
[22.]
M. Palmqvist, P. Arvidsson, O. Beckman, S. Peterson, J. Lötvall.
Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers.
Pulm Pharmacol Ther, 14 (2001), pp. 29-34
[23.]
M. Cazzola, P. Santus, F. Di Marco, B. Boveri, F. Castagna, P. Carlucci, et al.
Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
Respir Med, 97 (2003), pp. 453-457
[24.]
J. Bourbeau, S.J. Bartlett.
Patient adherence in COPD.
Thorax, 63 (2008), pp. 831-838
[25.]
E. Jung, A.S. Pickard, J.W. Salmon, B. Bartle, T.A. Lee.
Medication adherence and persistence in the last year of life in COPD patients.
Respir Med, 103 (2009), pp. 525-534
[26.]
A. Lindberg, Z. Szalai, T. Pullerits, E. Radeczky.
Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Respirology, 12 (2007), pp. 732-739
[27.]
T. Welte, M. Miravitlles, P. Hernandez, G. Eriksson, S. Peterson, T. Polanowski, et al.
Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 180 (2009), pp. 741-750
[28.]
M.R. Partridge, W. Schuermann, O. Beckman, T. Persson, T. Polanowski.
Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasonein patients with COPD.
Ther Adv Respir Dis, 3 (2009), pp. 1-11
[29.]
P. Van der Valk, E. Monninkhof, J. Van der Palen, G. Zielhuis, C. Van Herwaarden.
Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study.
Am J Respir Crit Care Med, 166 (2002), pp. 1358-1363
Copyright © 2010. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología

Subscribe to our newsletter

Article options
Tools

Are you a health professional able to prescribe or dispense drugs?